Health Care·Biotechnology·$20.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.31 | N/A | +13.89% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.31 | N/A | +13.89% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious outlook, emphasizing their focus on mRNA technology. They acknowledged the challenges in the current market environment.
We are focused on advancing our mRNA technology platform.
Current market conditions are challenging, but we remain committed to our pipeline.
Moderna's earnings report shows a loss per share that was slightly better than expected, but the lack of revenue data and guidance contributed to a stock decline of 3.39%. Investors may be concerned about the company's future performance, especially given the current market challenges. The focus on mRNA technology remains a key point for the company's strategy moving forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MARATHON PETE CORP
Aug 3, 2020